Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | EV-201: enfortumab vedotin for bladder cancer

Daniel Petrylak • 2 Jun 2019
ASCO 2019
Bladder Cancer Genitourinary Cancer Enfortumab vedotin

Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, tells about the EV-201 bladder cancer study (NCT03219333) which investigated enfortumab vedotin for patients with locally advanced or metastatic urothelial bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
0:24
HER2-targeting ADCs for urothelial carcinoma
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals